Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck
Third Quarter 2024 Financial Results
- Third quarter 2024 Total revenue of
$89 million , up from$55 million in the comparable prior year period, an increase of 61% driven by$45 million of non-cash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was$44 million , a decrease of 21% over the prior year period- Excluding the
$45 million non-cash deferred revenue release, third quarter 2024 Cell Engineering revenue of$30 million , down from$37 million in the comparable prior year period, a decrease of 20% driven by the continued shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring - Third quarter 2024 Biosecurity revenue of
$14 million with gross profit margin of 28%. Biosecurity revenue decreased from the comparable prior year period due to the expected ramp down of K-12 testing
- Excluding the
- Third quarter 2024 Loss from operations of
$(55) million (inclusive of stock-based compensation expense of$14 million and M&A and restructuring related costs of$2 million , net), compared to Loss from operations of$(286) million (inclusive of stock-based compensation expense of$54 million and M&A and restructuring related costs, including asset impairments, of$124 million ) in the comparable prior year period. The 2024 period also benefited from the above non-cash deferred revenue release - Third quarter 2024 Adjusted EBITDA of
$(20) million , up from$(84) million in the comparable prior year period, driven by the above non-cash deferred revenue release and a decrease in operating expenses - Cash and cash equivalents balance as of the end of the third quarter of
$616 million
"I'm extremely proud of the significant progress we made in the third quarter," said
Recent Business Highlights & Strategic Positioning
- Cell Engineering closed deals with new and existing customers
- Added 25 new programs and other customer contracts to the Cell Engineering platform in Q3 2024, of which 11 were comparable in size and scope to historically reported New Programs and an additional 14 contracts that represent a variety of other deal archetypes, such as Datapoints projects
- Signed a new deal with Novo Nordisk focused on the discovery and development of proteins while also expanding Ginkgo's existing collaboration on expression systems for pharmaceutical products
- Delivered on a major research milestone for Ginkgo's previously announced deal with Merck. As part of this milestone completion, Ginkgo will receive a fee of
$9 million in cash, expected in Q4 2024, and will move to Stage 2 to work towards making an even more effective production process - Signed three new Datapoints deals with a major TechBio company and two of the top 25 pharmaceutical companies
- Ginkgo Biosecurity continues to work towards creating solutions that offer persistent, pervasive monitoring
- Ginkgo validated its approach to rapidly detect H5N1 and has updated its offerings to include DNA sequencing of raw milk, bioinformatics as a service and comprehensive analyzed data sets
- Ginkgo made significant progress on its plan to reach Adjusted EBITDA breakeven by the end of 2026
- The reduction in force is estimated to achieve over
$85 million in annualized savings by mid-2025 - Ginkgo has continued implementing significant non-people cost cutting measures, including rationalizing third-party costs and site consolidation
- The reduction in force is estimated to achieve over
- Dr.
Sri Kosuri , CEO of Octant and former associate professor atUCLA in theChemistry and Biochemistry Department , joined our Board onNovember 6, 2024 . Dr.Arie Belldegrun , a director sinceSeptember 2021 and member of our compensation committee, resigned from the Board onNovember 7, 2024
Full Year 2024 Outlook
- Ginkgo previously issued 2024 guidance for Total revenue of
$170-190 million ; Cell Engineering services revenue of$120-140 million ; and Biosecurity revenue of at least$50 million . Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned$45 million non-cash deferred revenue release in the third quarter to:- Total revenue guidance of
$215-235 million in 2024; - Cell Engineering services revenue of
$165-185 million in 2024; and - Biosecurity revenue of at least
$50 million in 2024.
- Total revenue guidance of
Conference Call Details
Ginkgo will host a videoconference today,
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/
Audio-Only Dial Ins:
+1 646 876 9923 (
+1 301 715 8592 (
+1 312 626 6799 (
+1 669 900 6833 (
+1 253 215 8782 (Tacoma)
+1 346 248 7799 (
+1 408 638 0968 (
Webinar ID: 920 8859 2008
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About
Forward-Looking Statements of
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven and profitability, our reduction in workforce and anticipated impacts thereof, the timing and structuring of our facilities consolidation and the potential financial impact thereof, potential customer success, including successful application of our offerings by our customers, expectations with regard to revenue, expenses, including our stock-based compensation expenses, our full year 2024 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development or commercialization success of our customers, and (xi) the potential negative impact on our business of our planned reduction in force or the failure to realize the anticipated savings associated therewith. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the
Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
|
|
|||||
|
Condensed Consolidated Balance Sheets |
|||||
|
(in thousands, except per share data, unaudited) |
|||||
|
|
|
|
|
|
|
|
|
|
As of |
|
As of |
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ 616,214 |
|
$ 944,073 |
|
|
Accounts receivable, net |
|
23,411 |
|
17,157 |
|
|
Accounts receivable - related parties |
|
531 |
|
742 |
|
|
Prepaid expenses and other current assets |
|
22,324 |
|
39,777 |
|
|
Total current assets |
|
662,480 |
|
1,001,749 |
|
|
Property, plant, and equipment, net |
|
211,035 |
|
188,193 |
|
|
Operating lease right-of-use assets |
|
405,911 |
|
206,801 |
|
|
Investments |
|
62,103 |
|
78,565 |
|
|
Intangible assets, net |
|
79,566 |
|
82,741 |
|
|
|
|
— |
|
49,238 |
|
|
Other non-current assets |
|
59,788 |
|
58,055 |
|
|
Total assets |
|
$ 1,480,883 |
|
$ 1,665,342 |
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ 15,700 |
|
$ 9,323 |
|
|
Deferred revenue |
|
22,894 |
|
44,486 |
|
|
Accrued expenses and other current liabilities |
|
75,833 |
|
110,051 |
|
|
Total current liabilities |
|
114,427 |
|
163,860 |
|
|
Non-current liabilities: |
|
|
|
|
|
|
Deferred revenue, net of current portion |
|
105,247 |
|
158,062 |
|
|
Operating lease liabilities, non-current |
|
445,592 |
|
221,835 |
|
|
Other non-current liabilities |
|
17,674 |
|
24,433 |
|
|
Total liabilities |
|
682,940 |
|
568,190 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
Preferred stock, |
|
— |
|
— |
|
|
Common stock, |
|
5 |
|
5 |
|
|
Additional paid-in capital |
|
6,527,698 |
|
6,386,191 |
|
|
Accumulated deficit |
|
(5,730,023) |
|
(5,290,528) |
|
|
Accumulated other comprehensive income |
|
263 |
|
1,484 |
|
|
Total stockholders' equity |
|
797,943 |
|
1,097,152 |
|
|
Total liabilities and stockholders' equity |
|
$ 1,480,883 |
|
$ 1,665,342 |
|
|
|
|||||||||
|
Condensed Consolidated Statements of Operations and Comprehensive Loss |
|||||||||
|
(in thousands, except per share data, unaudited) |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
|
Cell Engineering revenue |
|
$ 75,089 |
|
$ 37,176 |
|
$ 139,183 |
|
$ 116,555 |
|
|
Biosecurity revenue: |
|
|
|
|
|
|
|
|
|
|
Product |
|
— |
|
6,495 |
|
— |
|
28,949 |
|
|
Service |
|
13,957 |
|
11,759 |
|
44,013 |
|
71,196 |
|
|
Total revenue |
|
89,046 |
|
55,430 |
|
183,196 |
|
216,700 |
|
|
Costs and operating expenses: |
|
|
|
|
|
|
|
|
|
|
Cost of Biosecurity product revenue |
|
— |
|
906 |
|
— |
|
7,481 |
|
|
Cost of Biosecurity service revenue |
|
9,987 |
|
6,017 |
|
30,996 |
|
39,913 |
|
|
Cost of other revenue |
|
2,016 |
|
— |
|
3,930 |
|
— |
|
|
Research and development (1) |
|
77,006 |
|
156,662 |
|
347,684 |
|
463,583 |
|
|
General and administrative (1) |
|
52,292 |
|
82,028 |
|
188,864 |
|
295,802 |
|
|
Impairment of lease assets |
|
— |
|
96,210 |
|
— |
|
96,210 |
|
|
|
|
— |
|
— |
|
47,858 |
|
— |
|
|
Restructuring charges |
|
2,949 |
|
— |
|
20,015 |
|
— |
|
|
Total operating expenses |
|
144,250 |
|
341,823 |
|
639,347 |
|
902,989 |
|
|
Loss from operations |
|
(55,204) |
|
(286,393) |
|
(456,151) |
|
(686,289) |
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
Interest income, net |
|
9,251 |
|
15,020 |
|
31,275 |
|
43,914 |
|
|
Loss on equity method investments |
|
— |
|
— |
|
— |
|
(1,516) |
|
|
Loss on investments |
|
(6,912) |
|
(36,324) |
|
(16,282) |
|
(44,815) |
|
|
Loss on deconsolidation of subsidiary |
|
(7,013) |
|
— |
|
(7,013) |
|
— |
|
|
Change in fair value of warrant liabilities |
|
1,528 |
|
1,891 |
|
5,701 |
|
(1,387) |
|
|
Other income, net |
|
1,572 |
|
2,893 |
|
2,821 |
|
9,045 |
|
|
Total other income (expense) |
|
(1,574) |
|
(16,520) |
|
16,502 |
|
5,241 |
|
|
Loss before income taxes |
|
(56,778) |
|
(302,913) |
|
(439,649) |
|
(681,048) |
|
|
Income tax expense (benefit) |
|
(375) |
|
(22) |
|
(154) |
|
127 |
|
|
Net loss |
|
$ (56,403) |
|
$ (302,891) |
|
$ (439,495) |
|
$ (681,175) |
|
|
Net loss per share, basic and diluted |
|
$ (1.08) |
|
$ (6.21) |
|
$ (8.58) |
|
$ (14.09) |
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
Basic |
|
52,240 |
|
48,770 |
|
51,244 |
|
48,330 |
|
|
Diluted |
|
52,246 |
|
48,770 |
|
51,250 |
|
48,330 |
|
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ (56,403) |
|
$ (302,891) |
|
$ (439,495) |
|
$ (681,175) |
|
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
494 |
|
(1,599) |
|
(2,713) |
|
(267) |
|
|
Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary |
|
1,492 |
|
— |
|
1,492 |
|
— |
|
|
Total other comprehensive income (loss) |
|
1,986 |
|
(1,599) |
|
(1,221) |
|
(267) |
|
|
Comprehensive loss |
|
$ (54,417) |
|
$ (304,490) |
|
$ (440,716) |
|
$ (681,442) |
|
|
|
|||||||||
|
(1) Total stock-based compensation expense, inclusive of employer payroll taxes, was allocated as follows (in thousands): |
|||||||||
|
|
|||||||||
|
|
|
Three Months Ended |
|
Nine Months Ended |
|||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
|
Research and development |
|
$ 3,214 |
|
$ 33,976 |
|
$ 48,028 |
|
$ 122,086 |
|
|
General and administrative |
|
10,799 |
|
19,671 |
|
46,608 |
|
69,238 |
|
|
Total |
|
$ 14,013 |
|
$ 53,647 |
|
$ 94,636 |
|
$ 191,324 |
|
|
|
||||
|
Condensed Consolidated Statements of Cash Flows |
||||
|
(in thousands, unaudited) |
||||
|
|
|
|
|
|
|
|
|
Nine Months Ended |
||
|
|
|
2024 |
|
2023 |
|
Cash flows from operating activities: |
|
|
|
|
|
Net loss |
|
$ (439,495) |
|
$ (681,175) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
Depreciation and amortization |
|
47,368 |
|
57,670 |
|
Stock-based compensation |
|
91,783 |
|
187,047 |
|
|
|
47,858 |
|
— |
|
Restructuring related impairment charges |
|
4,823 |
|
— |
|
Loss on investments and equity method investments |
|
16,282 |
|
46,331 |
|
Loss on deconsolidation of subsidiary |
|
7,013 |
|
— |
|
Change in fair value of warrant liabilities |
|
(5,701) |
|
1,387 |
|
Change in fair value of contingent consideration liability |
|
3,698 |
|
10,217 |
|
Non-cash lease expense |
|
20,619 |
|
24,635 |
|
Non-cash in-process research and development |
|
19,796 |
|
3,981 |
|
Impairment of long-lived assets |
|
— |
|
121,404 |
|
Other non-cash activity |
|
655 |
|
3,053 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
Accounts receivable |
|
(6,101) |
|
21,168 |
|
Prepaid expenses and other current assets |
|
3,487 |
|
13,557 |
|
Operating lease right-of-use assets |
|
19,224 |
|
9,277 |
|
Other non-current assets |
|
(196) |
|
(2,733) |
|
Accounts payable, accrued expenses and other current liabilities |
|
(31,099) |
|
(4,822) |
|
Deferred revenue, current and non-current |
|
(67,779) |
|
(29,382) |
|
Operating lease liabilities, current and non-current |
|
(11,383) |
|
(18,310) |
|
Other non-current liabilities |
|
1,998 |
|
(974) |
|
Net cash used in operating activities |
|
(277,150) |
|
(237,669) |
|
Cash flows from investing activities: |
|
|
|
|
|
Purchases of property and equipment |
|
(48,831) |
|
(37,355) |
|
Business acquisition |
|
(5,400) |
|
— |
|
Proceeds from sales of marketable securities |
|
3,951 |
|
— |
|
Proceeds from sale of equipment |
|
591 |
|
3,000 |
|
Other |
|
538 |
|
336 |
|
Net cash used in investing activities |
|
(49,151) |
|
(34,019) |
|
Cash flows from financing activities: |
|
|
|
|
|
Proceeds from exercise of stock options |
|
84 |
|
79 |
|
Principal payments on finance leases |
|
(694) |
|
(977) |
|
Contingent consideration payment |
|
(922) |
|
(1,082) |
|
Other |
|
(4) |
|
(604) |
|
Net cash used in financing activities |
|
(1,536) |
|
(2,584) |
|
Effect of foreign exchange rates on cash and cash equivalents |
|
(208) |
|
(690) |
|
Net decrease in cash, cash equivalents and restricted cash |
|
(328,045) |
|
(274,962) |
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of period |
|
944,073 |
|
1,315,792 |
|
Restricted cash, beginning of period |
|
45,511 |
|
53,789 |
|
Cash, cash equivalents and restricted cash, beginning of period |
|
989,584 |
|
1,369,581 |
|
|
|
|
|
|
|
Cash and cash equivalents, end of period |
|
616,214 |
|
1,049,244 |
|
Restricted cash, end of period |
|
45,325 |
|
45,375 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ 661,539 |
|
$ 1,094,619 |
|
Selected Non-GAAP Financial Measures |
||||||||
|
(in thousands, unaudited) |
||||||||
|
|
||||||||
|
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
Net loss (1) |
|
$ (56,403) |
|
$ (302,891) |
|
$ (439,495) |
|
$ (681,175) |
|
Interest income, net |
|
(9,251) |
|
(15,020) |
|
(31,275) |
|
(43,914) |
|
Income tax expense (benefit) |
|
(375) |
|
(22) |
|
(154) |
|
127 |
|
Depreciation and amortization |
|
17,171 |
|
21,060 |
|
47,368 |
|
57,670 |
|
EBITDA |
|
(48,858) |
|
(296,873) |
|
(423,556) |
|
(667,292) |
|
Stock-based compensation (2) |
|
14,013 |
|
53,647 |
|
94,636 |
|
191,324 |
|
Impairment expense (3) |
|
— |
|
112,403 |
|
47,858 |
|
121,404 |
|
Restructuring charges (4) |
|
2,949 |
|
— |
|
20,015 |
|
— |
|
Merger and acquisition related expenses (5) |
|
(796) |
|
12,253 |
|
6,110 |
|
43,127 |
|
Loss on equity method investments |
|
— |
|
— |
|
— |
|
1,516 |
|
Loss on investments |
|
6,912 |
|
36,324 |
|
16,282 |
|
44,815 |
|
Loss on deconsolidation of subsidiary |
|
7,013 |
|
— |
|
7,013 |
|
— |
|
Change in fair value of warrant liabilities |
|
(1,528) |
|
(1,891) |
|
(5,701) |
|
1,387 |
|
Change in fair value of convertible notes |
|
281 |
|
317 |
|
1,127 |
|
121 |
|
Adjusted EBITDA |
|
$ (20,014) |
|
$ (83,820) |
|
$ (236,216) |
|
$ (263,598) |
|
|
|
|
(1) |
All periods include non-cash revenue when earned, including |
|
(2) |
Includes |
|
(3) |
For 2024, includes |
|
(4) |
Restructuring charges consist of employee termination costs from the reduction in force commenced in |
|
(5) |
Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery. Not included in this adjustment are non-cash charges for acquired in-process research and development expenses, which totaled |
|
|
|||||||
|
Segment Information |
|||||||
|
(in thousands, unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
Revenue: |
|
|
|
|
|
|
|
|
Cell Engineering |
$ 75,089 |
|
$ 37,176 |
|
$ 139,183 |
|
$ 116,555 |
|
Biosecurity |
13,957 |
|
18,254 |
|
44,013 |
|
100,145 |
|
Total revenue |
89,046 |
|
55,430 |
|
183,196 |
|
216,700 |
|
Segment cost of revenue: |
|
|
|
|
|
|
|
|
Cell Engineering |
2,016 |
|
— |
|
3,930 |
|
— |
|
Biosecurity |
9,987 |
|
6,923 |
|
30,996 |
|
47,394 |
|
Segment research and development expense: |
|
|
|
|
|
|
|
|
Cell Engineering |
57,201 |
|
90,889 |
|
253,790 |
|
275,494 |
|
Biosecurity |
141 |
|
313 |
|
720 |
|
1,408 |
|
Total segment research and development expense |
57,342 |
|
91,202 |
|
254,510 |
|
276,902 |
|
Segment general and administrative expense: |
|
|
|
|
|
|
|
|
Cell Engineering |
29,319 |
|
42,617 |
|
103,167 |
|
155,216 |
|
Biosecurity |
10,040 |
|
12,207 |
|
33,169 |
|
42,862 |
|
Total segment general and administrative expense |
39,359 |
|
54,824 |
|
136,336 |
|
198,078 |
|
Segment operating (loss) income: |
|
|
|
|
|
|
|
|
Cell Engineering |
(13,447) |
|
(96,330) |
|
(221,704) |
|
(314,155) |
|
Biosecurity |
(6,211) |
|
(1,189) |
|
(20,872) |
|
8,481 |
|
Total segment operating loss |
(19,658) |
|
(97,519) |
|
(242,576) |
|
(305,674) |
|
Operating expenses not allocated to segments: |
|
|
|
|
|
|
|
|
Stock-based compensation (1) |
14,013 |
|
53,647 |
|
94,636 |
|
191,324 |
|
Depreciation and amortization |
17,171 |
|
21,060 |
|
47,368 |
|
57,670 |
|
Impairment expense (2) |
— |
|
112,403 |
|
47,858 |
|
121,404 |
|
Restructuring charges |
2,949 |
|
— |
|
20,015 |
|
— |
|
Change in fair value of contingent consideration liability |
1,413 |
|
1,764 |
|
3,698 |
|
10,217 |
|
Loss from operations |
$ (55,204) |
|
$ (286,393) |
|
$ (456,151) |
|
$ (686,289) |
|
|
|
|
(1) |
Includes |
|
(2) |
For 2024, includes |
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-reports-third-quarter-2024-financial-results-302303182.html
SOURCE
